BioSpace News Archive

Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced financial results for the quarter and year ended December 31, 2022 and provided a business update.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its full-year 2022 financial results will be released after the markets close on Tuesday, March 28th.

Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets.

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the resignation of Chairman Robert I. Blum.

ThermoGenesis Holdings, Inc. today announced the closing of its previously announced purchase and sale of 1,071,429 shares of its common stock (or common stock equivalents) and warrants to purchase up to 1,071,429 shares of its common stock at a purchase price of $2.80 per share of common stock (or common stock equivalent) and associated warrant in a private placement priced at-the-market under Nasdaq rules.

Advamedica Inc., a biomaterial focused medtech startup today announced the US Food and Drug Administration (FDA) 510(k) clearance for its latest innovation, Ax-Surgi Surgical Hemostat.

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to four new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today announced that clinical data from multiple trials in relation to TYVYT® (sintilimab injection), Pemazyre® (pemigatinib) and IBI351 (KRASG12C inhibitor) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, April 14 - 19, 2023.

Today, Cleveland Clinic and IBM (NYSE: IBM) officially unveiled the first deployment of an onsite private sector IBM-managed quantum computer in the United States.

Prestige Biopharma has received Fast Track designation from the U.S. Food and Drug Administration for PBP1510, in the treatment of unresectable or metastatic pancreatic adenocarcinoma that has relapsed following and/or is refractory to at least one line of prior therapy.